Abstract
We report the synthesis and in vivo activity of a novel anti-atherogenic agent, isosteric selenium PPARδ-selective ligand. This ligand did not cause significant body or liver weight changes and did not have obvious adverse effects on intestinal polyp formation. Our overall results clearly demonstrate that PPARδ is a viable drug candidate for targeting and treating atherosclerosis.
Original language | English |
---|---|
Pages (from-to) | 7239-7242 |
Number of pages | 4 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 20 |
Issue number | 24 |
DOIs | |
State | Published - 15 Dec 2010 |
Bibliographical note
Funding Information:We are grateful to members of our laboratory. This work was supported by the Marine Biotechnology Program, Ministry of Land, Transport and Maritime Affairs (MLTM) and in part the BK21 program from Ministry of Education, Science and Technology (MEST), Korea.
Keywords
- Anti-atherogenic agents
- Intestinal polyp formation
- PPARδ-selective ligand